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Pulmonary arterial hypertension (PAH) is commonly treated with pulmonary arteriolar vasodilator therapy. When a
patient on PAH medication is admitted to intensive care, determining how to manage their medication during the
critical illness is often complicated. There may be considerations related to the inability to take medication by
mouth, related to acute renal failure or acute liver injury, related to altered mental status or delirium, or related to
hypotension and bacteremia. Decisions of how to manage these medications can have a major impact on the
patient’s clinical course. Presently, provider experience is the major tool in navigating the decisions regarding these
medications. In this review, we offer our recommendations of how to manage PAH patients with critical illness who
are on PAH medications. These recommendations include how to deliver medications via feeding tubes, how to
dose medications in the setting of acute renal failure or acute liver failure, and how to manage medications during
hypotension or when a tunneled catheter needs to be removed.Introduction
Pulmonary arterial hypertension (PAH) is a progressive
disorder of the pulmonary circulation, which leads to right
ventricular failure and death. In the past two decades, ad-
vances have led to US Food and Drug Administration ap-
proval of several PAH therapies for the treatment of PAH,
and their use is now widespread. Common side effects
and use of these medications in the outpatient setting have
been extensively discussed. However, we are unaware of a
review of PAH therapies focusing on management when
patients are admitted to an ICU. Many patients with PAH
die in an ICU setting [1,2], and the reported prevalence of
PAH may have increased from the 1980s, when a National
Institutes of Health registry enrolled less than 200 patients
[3], to the present, with more than 3,500 patients enrolled
in the US-based Registry to Evaluate Early and Long-term
PAH Disease Management (REVEAL) [4]. A discussion of
how to manage existing PAH therapies in patients admit-
ted to the ICU is therefore overdue. This management
includes the use of phosphodiesterase inhibitors, endothelin* Correspondence: dcgrinnan@vcu.edu
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unless otherwise stated.receptor antagonists and prostacyclin analogs. Our discus-
sion will not include fluid management of PAH patients
admitted to the ICU, because this topic has previously
been discussed in other publications [5,6].
At our institution, we routinely care for patients on treat-
ment for PAH during inpatient admissions. Often this in-
cludes transfer from another hospital. Over the past decade,
we average over 30 PAH patients per year admitted with
varying conditions. We offer our single-center experience
with PAH therapies in the ICU setting, as well as our rec-
ommended approach to their use during ICU admission.
Medication administration during critical illness
Administration of medications may be compromised
when patients require mechanical ventilation and enteral
nutrition, but it is possible via an enteral feeding tube if
the drug formation is suitable for enteral administration.
Generally, liquid formulations are preferred over tablet or
capsule dosage forms [7]. In the absence of a liquid dosage
form, many solid dosage forms (tablets or capsules) can be
crushed or opened and mixed with water for enteral ad-
ministration. Dosage forms that should not be altered for
enteral administration include those of extended or delayed
release, and drugs with chemotherapeutic, teratogenic orral Ltd. The licensee has exclusive rights to distribute this article, in any medium,
this time, the article is available under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0) applies to the data made available in this article,
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(sildenafil and tadalafil), endothelin receptor antagonists
(bosentan, ambrisentan and macitentan) and the novel
soluble guanylate cyclase stimulator (riociguat) are oral
medications for the treatment of PAH. Table 1 presents
recommendations for the administration of these oral
medications via enteral feeding tube. Additionally, nursing
staff should be given detailed instructions regarding proper
enteral drug administration procedures [7].
Administration of inhaled outpatient therapy is prob-
lematic when patients require mechanical ventilation.
Products such as iloprost (Ventavis®; Actelion Pharma-
ceuticals, San Francisco, CA, USA) and treprostinil
(Tyvaso®; United Therapeutics, Research Triangle Park,
NC, USA) require delivery with specialized delivery de-
vices: iloprost, I-neb® Adaptive Aerosol Delivery® (Philips
Healthcare, Andover, MA, USA) or Prodose® Adaptive
Aerosol Delivery® (Philips Healthcare) [20]; and trepros-
tinil, Tyvaso inhalation system® (United Therapeutics)
[21]. Although reports exist of successful inhaled ilo-
prost delivery to patients requiring mechanical ventila-
tion or high-flow oxygen [22], this delivery method has
not been extensively tested, nor is it approved by the US
Food and Drug Administration. Furthermore, patients re-
quiring mechanical ventilation may benefit from a titrat-
able medication that is delivered continuously rather than
intermittently. Hence continuous administration of pul-
monary vasodilator therapy (nebulized epoprostenol or
inhaled nitric oxide) may be advantageous because of
the ability to titrate the dose and the likelihood that
continuous drug delivery will be less likely to alter hemo-





Sildenafil [8-10] Yes Yes (dosage is 10 mg
every 8 hours)
Tadalafil [11,12] Noa No
Bosentan [13-16] Noa No
Ambrisentan [14,17] No No
Macitentan [18] No No
Riociguat [19] No No
aMay be compounded as follows: grind 15 tadalafil 20 mg tablets in a glass mortar,
and 30 ml Ora-Sweet (Paddock Laboratories) to make a final volume of 60 ml. Susp
room temperature. bMay be compounded as follows: place bosentan tablet in 5 to
can be used to deliver the prescribed dose. Any remaining suspension should be d
(acidic) pH (for example, fruit juices) due to poor solubility; the drug is most soluble
not handle crushed bosentan.Altered mental status section for more on inhaled nitric
oxide and nebulized epoprostenol).
Bacteremia and sepsis
The incidence of bacteremia in patients with PAH is ele-
vated compared with that in the general public. This is
secondary to the central venous catheters used to deliver
intravenous prostanoid therapy [23]. The incidence of
bacteremia has been estimated at 0.118 episodes per 1,000
treatment-days in patients receiving epoprostenol and as
0.938 episodes per 1,000 treatment-days in patients receiv-
ing treprostinil [24]. Although improvements in adminis-
tration techniques may further decrease the incidence of
bacterial infection associated with treprostinil therapy,
bloodstream infections may still occur [25]. When a pa-
tient develops bacteremia with or without sepsis there are
difficult questions that arise.
First, it is important to address whether or not a tun-
neled catheter used for prostacyclin infusion should be
removed in the setting of bacteremia or sepsis. We agree
with current Infectious Diseases Society of America
guidelines that any patient with sepsis should have the
indwelling catheter removed after alternate access is ob-
tained and the prostacyclin infusion is transferred [26].
We also feel that patients with known bacteremia and
tachycardia, even if not fulfilling the criteria for sepsis,
should have consideration of catheter removal. This is
due to the risk that tachycardia and systemic vasodilata-
tion from bacteremia may pose to the right ventricle that
is already strained from PAH. If a patient is bacteremic
but normotensive and without tachycardia, then culture
results can be awaited while antibiotics are administered,onary arterial hypertension medications
on Data supporting enteral drug administration
Reports exist where sildenafil tablet was crushed, dissolved
in 5 ml sterile water and administered via enteral tube
No data available. May be reasonable to use extemporaneous
preparation of tadalafil suspension for enteral administration
Institute for Safe Medication Practices does not recommend
crushing due to teratogenic propertiesb
Institute for Safe Medication Practices: ‘do not crush medication’
(extended release product with teratogenic properties);
do not administer via enteral tube
Manufacturer recommends that tablets not be split, chewed
or crushed; do not administer via enteral tube
No data available; would not recommend crushing due
to teratogenic properties
then mix with 30 ml Ora-Plus (Paddock Laboratories, Minneapolis, MN, USA)
ension is stable for at least 91 days when stored in amber plastic bottles at
25 ml water to create a suspension. An appropriate aliquot of the suspension
iscarded. Bosentan should not be mixed or dissolved in liquids with a low
in solutions with pH >8.5. Women who are or may become pregnant should




















0.01 to 3.6 0.002 to
1.00
0.05 to 5 0.1 to
999 [27]
aSmiths Medical, St Paul, MN, USA. bIntra Pump Infusion Services, Grapevine, TX,
USA. cCareFusion, San Diego, CA, USA. CADD, computerized ambulatory
drug delivery.
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and enterococcus may not necessitate catheter removal
[26]. If a decision is made to remove the catheter, alter-
native access must be obtained prior to catheter removal
to ensure continuous prostacyclin delivery. Central ven-
ous access (including peripherally inserted central cathe-
ters) is preferred over peripheral intravenous lines, due
to the less stable nature of peripheral lines. If the
inserted central catheter has multiple lumens, we recom-
mend labeling or marking the lumen through which
prostacyclin will infuse. In this way, the possibility of
manipulating the prostacyclin line will be minimized. In
general, once a tunneled catheter is removed due to in-
fection with bacteremia, it should not be replaced until
the patient has completed a full course of antibiotics and
has negative blood cultures. Replacement of the tun-
neled catheter is generally done in the outpatient setting
after recovery.
Second, if the central venous catheter associated with
prostacyclin infusion is a potential source of bacteremia
and needs to be removed, how should the prostacyclin
infusion be managed? Possible solutions to this question
include: rapidly transferring the infusion from the old
catheter to the new catheter without priming the new
catheter (discouraged in most cases, see below); priming
the new catheter with medication prior to rapid transfer-
ence of the infusion to the new catheter; or overlapping
infusions, with one running through the old catheter
until a volume is instilled in the new catheter that ap-
proximates the volume of that catheter. Variables in-
volved in this decision include the dead space present in
the catheter (Table 2), the pump infusion rate (Table 3),
the half-life of the infusing medication and the patient’s
condition [27-29].
While Table 2 presents a guide for the volume of vari-
ous catheters, Hickman catheters are often cut to patient
length and may have a different volume than anticipated.
Measuring the cut catheter volume with saline prior to
insertion can provide the volume of the catheter in this
instance. While several centers have a policy of priming
0.75 ml medication from a computerized ambulatoryTable 2 Volumes associated with various catheter types
Catheter type Catheter volume
55 cm PICC line, 17 gauge lumen 0.76 ml [28]
55 cm PICC line, 18 gauge lumen 0.56 to 0.68 ml [28]
55 cm PICC line, 19 gauge lumen 0.44 ml [28]
Single-lumen Hickman catheter, 9.6 French 1.8 ml [28]
Double-lumen Hickman catheter, 9 French 0.6 ml (small port),
1.3 ml (large port) [28]
Triple-lumen catheter 0.38 ml (18 gauge ports),
0.42 ml (16 gauge ports) [29]
PICC, peripherally inserted central catheter.drug delivery (CADD) Legacy pump (Smiths Medical, St
Paul, MN, USA) into the new catheter before rapid se-
quence transfer of medication (personal communication
with other pulmonary hypertension practitioners and
specialty pharmacies), this does not account well for the
above variables. If a treprostinil infusion is transitioned
from a Hickman catheter to a peripherally inserted cen-
tral catheter line, a nontunneled central venous catheter,
or a peripheral intravenous catheter, then a rapid transi-
tion without priming is usually well tolerated, as the
medication will be delivered systemically prior to a half-
life elimination. This is contrasted with a transition from
a peripherally inserted central catheter line to a single
lumen Hickman catheter. Because of the large catheter
volume of the Hickman catheter, the time from initiation
of infusion to systemic delivery could be as long as
90 hours (for a slowly infusing treprostinil infusion from
a CADD-MS3 pump (Smiths Medical)), much longer
than the 4.5-hour half-life of the medication. Similarly, a
patient receiving intravenous therapy (epoprostenol or
treprostinil) from a CADD Legacy pump could have a
delay from initiation to systemic delivery of 1 to 2 hours,
much longer than the half-life of 3 to 6 minutes. In both
examples, consideration must be given to either overlap-
ping the infusions or priming the new catheter with
medication, so that excessive time without medication
can be avoided. Of these two options, we prefer overlap-
ping medication, because this will prevent the potentially
ill-effects of inadvertent drug bolus administration while
priming the new line (in our experience, even a bolus of
one-half the catheter volume instilled over 5 to 10 mi-
nutes can lead to symptoms of prostacyclin toxicity). We
believe that symptoms of prostacyclin excess can occur
with catheter priming due to rapid instillation of product
into the catheter causing unintended transference of
medication systemically.
Third, should the patient remain on their existing infu-
sion pump, or should the patient be transitioned to a hos-
pital pump? There are potential advantages and pitfalls to
each approach. If the patient remains on their pump, the
hospital staff may be unfamiliar with the pump and unable
to alter the infusion. This places the responsibility of man-
aging the infusion pump on the patient or their mixing
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vironment, they may be more prone to medication error. If
the pump is under the care of a mixing partner, they may
be unavailable to change the medication when needed, and
user error is again a concern. However, if the decision is
made to change the infusion to a hospital pump, a change
in medication concentration may be required due to limi-
tations in infusion rates on the hospital pump (see Table 3).
A change in medication concentration could lead to wide
changes in drug delivery to the patient. For example, if a
patient weighing 60 kg usually receives 100 ng/kg/minute
treprostinil (10 mg/ml) delivered by CADD-MS3 pump at
a rate of 0.036 ml/hour through a Hickman catheter with
volume of 1.8 ml, and they are changed to a hospital
pump requiring a change in treprostinil concentration
to 1 mg/ml treprostinil so that an equivalent dose can be
maintained at a rate of 0.36 ml/hour, then the first 5 hours
of infusion through the hospital pump will infuse the
remaining 10 mg/ml treprostinil indwelling in the cath-
eter, which could deliver a dose 10 times that intended.
Even among pulmonary hypertension centers, the de-
cision of whether to transition from patient pump to
hospital pump is debatable and clinical practice varies
significantly [30]. In our institution, all medication is
supplied from pharmacy with mixing instructions
checked among members of our PAH team from nursing,
pharmacy and physicians. On our pulmonary hypertension
unit, where all nurses are regularly in-serviced on pumps
and are familiar with infusions, patients may stay on their
own pump with nursing assisting with management. In
our ICU, where nurses may have little prostacyclin experi-
ence, patients on CADD Legacy pumps are transitioned to
hospital pumps, as the rate and concentration of infusion
can often be left unchanged. However, patients on CADD-
MS3 pumps in our ICU are not transitioned, due to the in-
ability to match the rate and concentration on hospital
pumps.
As infused prostacyclin therapy is intricate in its delivery,
and errors in management could have significant deleteri-
ous effects, we recommend that management of inpatients
on prostacyclin therapy be managed at pulmonary hyper-
tension centers. This ensures a multidisciplinary approach
in which pharmacy, nursing and practitioners have signifi-
cant experience to minimize error. It is also important to
know that specialty pharmacies which deliver prostacyclin
therapy have nursing experiences with pump therapy avail-
able at all times to help manage issues with pump therapy.
Fourth, how should oral or inhaled medication be man-
aged in patients with hypotension related to sepsis? If a pa-
tient develops hypotension while on treatment for PAH,
then clinical management must be individualized. The con-
cern is that the pulmonary vasodilators used to treat PAH
cause some systemic vasodilatation. In the setting of
hypotension from sepsis, continued use of medications thatpotentiate hypotension could decrease perfusion and lead
to further end-organ dysfunction. We would rarely recom-
mend that a prostacyclin infusion be altered or decreased,
even if vasopressor support is indicated. If prostacyclin
infusion is decreased in an attempt to improve sys-
temic blood pressure, this should be done under the
direction of a practitioner with extensive prostacyclin
experience. If a patient is on oral medication and be-
comes hypotensive, the decision to hold these medica-
tions depends on certain variables. The risk of acutely
stopping these medications is difficult to determine. Fac-
tors such as the degree of hypoxemia, the extent of right
ventricular dysfunction and whether the right ventricle
is in compensated or decompensated failure may affect
management. This must be balanced with the risk of
continuing oral medications, because they can potentiate
hypotension and cause a resultant decrease in organ per-
fusion in the setting of sepsis. In the absence of sig-
nificant right ventricular failure in a patient with evidence
of end-organ hypoperfusion, then consideration of dose
decrease (if possible) or even cessation of oral medication
is necessary.
Altered mental status
Delirium and sedation are common in the ICU setting, af-
fecting up to 82% of ICU patients [31]. Altered mental sta-
tus can have a significant impact on medication delivery
of patients with PAH. Oral medications can usually be
managed as described in Table 1. Pump infusion can be-
come more complicated, especially if the patient has been
involved in the process of mixing and pump management.
When a patient is unable to care for a pump on their own,
and if they are far away from their home, it may be diffi-
cult to rely on their mixing partner to care for the infu-
sion. Therefore, it is essential that the healthcare system
develops a plan to care for the infusion, or quickly transfer
the patient to a facility with more experience, as described
in the Bacteremia and sepsis section above.
If a patient is on an inhaled therapy and develops altered
mental status, they will be unable to use this medication
as it requires patient participation for drug delivery. An al-
ternative mode of delivery therefore needs to be estab-
lished. At our institution, this alternative typically involves
transition to continuous delivery of either inhaled epo-
prostenol or inhaled nitric oxide. While neither therapy
has been approved by the US Food and Drug Administra-
tion for ICU use in adult patients within the United States,
they both have established hemodynamic effects in pa-
tients with PAH, and one has not been shown superior to
the other [32]. Because of concerns associated with pos-
sible side effects from inhaled nitric oxide (nitrogen diox-
ide accumulation and methemoglobinemia [33]), as well
as the high cost of therapy, our institution usually initiates
inhaled epoprostenol.
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tients with pulmonary hypertension is unknown; however,
an inverse dose–response relationship exists between the
inhaled epoprostenol dose and pulmonary artery pressures
[34]. Dosing of inhaled epoprostenol reported in the pri-
mary literature is variable and ranges from 5 to 85 ng/kg/
minute [35]. At our institution, we generally start at a dose
of either 50 or 100 ng/kg/minute and titrate by oxygen
saturation values and pulmonary artery pressures (mea-
sured by echocardiogram), where our maximum dose is
100 ng/kg/minute and our minimum dose is 10 ng/kg/mi-
nute. As epoprostenol has an extremely short half-life,
dose adjustments are made as quickly as every 15 minutes.
The duration of therapy is variable and is based on patient
improvement and the ability to resume or up-titrate other
therapies. While most patients only require nebulized epo-
prostenol as a temporary bridge, durations of therapy ex-
ceeding 2 weeks have been reported [35]. We have also
worked to eliminate safety events by standardizing order-
ing of inhaled epoprostenol in our electronic record sys-
tem (Figure 1A) and by selecting the Aeroneb (Aerogen
Ltd, Dangan, Galway, Ireland) method of delivery [36] to
prevent any loss of airflow from nebulized delivery of
medication (Figure 1B). At our institution, we have used
either inhaled nitric oxide or inhaled epoprostenol in the
operating room and ICU settings for patients who are un-
able to receive inhaled prostacyclin therapies.
Need for gastrointestinal rest
There are many conditions in the ICU during which a
patient may not be able to take medications enterallyFigure 1 Standardization of inhaled epoprostenol in our electronic re
inhaled epoprostenol as ordered through our electronic medical record. Co
improve safety. IBW, ideal body weight. (B) Left: our set-up for delivering in
ventilation. Right: the Aeroneb (Aerogen Ltd, Dangan, Galway, Ireland) in re
found with repeated trial and error to optimize aerosol delivery without sig(nil per os). These include but are not limited to peri-
operative care, acute cholecystitis, acute pancreatitis and
bowel obstruction. When a patient is nil per os, they can
typically continue pump therapy or inhaled therapy with-
out change if their mental status is intact. The challenge is
whether or not oral medications require a transition to
other forms of therapy. Sildenafil is available intraven-
ously, and may be administered instead of oral dosing if
given at 50% of the typical oral dose [8]. Other oral medi-
cations are not available intravenously, and consideration
of alternate therapies is needed. The current symptoms of
the patient, as well as the estimated length a patient may
be nil per os, may influence whether a patient requires al-
ternate PAH treatment for an interval. If patients require
a transition, we often begin with inhaled delivery of in-
haled nitric oxide or inhaled epoprostenol (see Altered
mental status section above for details). As with all PAH
patients, evidence of right ventricular decompensation
may necessitate a transition to pump therapy.
Acute renal insufficiency/failure
Renal failure is prevalent among patients admitted to the
ICU. A study from September 2000 to December 2001
identified a point prevalence rate for developing acute
renal failure in the ICU ranging from 1.4 to 25.9%, where
the average point prevalence rate was 5.7% [37]. The risk
may be higher in PAH, as one study determined that 34%
of PAH patients hospitalized for right heart failure devel-
oped worsening renal function during hospitalization (de-
fined as a rise in creatinine of 0.3 mg/dl within the first
48 hours of admission) [38]. This phenomenon is probablycord system and the Aeroneb method of delivery. (A) Dosage of
ncentrations and dosages selected to minimize bag changes and to
haled epoprostenol through an aeroneb on patients with mechanical
lation to tubing placed after the ventilator filter. This position was
nificant deposition in ventilator tubing.
Table 4 Monitoring and dosage of pulmonary arterial hypertension pharmacotherapy in renal insufficiency
Drug Degree of renal elimination Dosage adjustments Monitoring Recommendations
Phosphodiesterase type 5 inhibitors
Sildenafil [8] Nonrenal metabolism to active
metabolites; 13% of dose excreted
in urine as metabolites
No dose adjustment is required. In patients
with CrCl ≤30 ml/minute, exposure to parent
drug and active metabolite increased twofold
Worsening of side effects (hypotension,
epistaxis, nasal congestion, headache,
dyspepsia, flushing, insomnia, erythema,
dyspnea and/or rhinitis)
Monitor for worsening of side effects
and decrease dosage if indicated.
Tadalafil [11] Nonrenal metabolism; however, renal
impairment results in twofold to
fourfold increase in tadalafil exposure
CrCl 31 to 80 ml/minute: start dosing at 20 mg
once daily; increase to 40 mg once daily based
on individual tolerability. CrCl ≤30 ml/minute
or hemodialysis: avoid use.
Worsening of side effects (hypotension,
headache)
Monitor for hypotension, consider dose
reduction. Severe impairment: hold dose
if side effects worsened
Endothelin-receptor antagonists
Ambrisentan [17] Nonrenal elimination No adjustment for mild–moderate renal failure;
severe renal failure and hemodialysis not studied
Fluid overload Hold if fluid overload is problematic
Bosentan [13] <3% eliminated in urine No adjustment necessary Fluid overload Hold if fluid overload is problematic
Macitentan [13] Nonrenal elimination No adjustment necessary Worsening of side effects (anemia,
nasopharyngitis, pharyngitis, bronchitis,
headache, influenza, and urinary
tract infection)
Likely safe to use in patients with renal
dysfunction
Soluble guanylate cyclase stimulator
Riociguat [19] 40% drug eliminated in urine
(mostly as inactive metabolites)
Not recommended in patients with
CrCl <15 ml/minute or those receiving dialysis
Possible hypotension bleeding or other
side effects (headache, dizziness,
dyspepsia/gastritis, nausea, diarrhea,
hypotension, vomiting, anemia,
gastroesophageal reflux, and constipation)
Monitor for hypotension, consider dose
reduction. Severe impairment (anuria):
hold dose if side effects worsened
Intravenous prostacyclin therapy
Epoprostenol [39,40] Nonrenal elimination; metabolites
recovered in urine, some of which
are minimally active
No adjustment necessary; if initiating therapy,
consider starting at a low dose and titrating slowly
Possible hypotension or side effects
(headache, jaw pain, flushing)
Titrate slowly during initiation phase; consider
gradual dosage reduction if patient is hypotensive
and experiencing increased side effects (flushing,
headache, jaw pain); do not abruptly discontinue
therapy
Treprostinil [41] 4% of unchanged drug eliminated
in urine; all metabolites (inactive)
renally eliminated
No specific recommendation available Possible hypotension or side effects
(headache, jaw pain, flushing)
Titrate slowly during initiation phase;
consider gradual dosage reduction if patient
is hypotensive and is experiencing increased
side effects (flushing, headache, jaw pain);
do not abruptly discontinue therapy
Inhaled vasodilators (prostacyclin and nonprostacyclin)
Inhaled nitric oxide
[42]
Combines with oxyhemoglobin to
produce methemoglobin and nitrate;
nitrate is renally eliminated
No dosage adjustments recommended/required Methemoglobin Probably safe to use in patients with renal
dysfunction
Treprostinil, inhaled [21] 4% of unchanged drug eliminated
in urine; all metabolites (inactive)
renally eliminated
No specific recommendation available Possible hypotension or side effects
(headache, jaw pain, flushing)
Titrate slowly during initiation phase; consider
increasing dosing interval if patient is
hypotensive and experiencing increased side
effects (flushing, headache, jaw pain)
Iloprost, inhaled [20] Nonrenal elimination Not studied in patients with renal impairment; based
on drug elimination, accumulation not expected
Possible syncope or side effects (headache,
flushing, dizziness, nausea, vomiting or diarrhea)
Probably safe for use in patients with renal














Table 5 Monitoring and dosage of pulmonary arterial hypertension pharmacotherapy in hepatic impairment
Drug Degree of hepatic elimination Dosage adjustments Monitoring Recommendations
Phosphodiesterase type 5 inhibitors
Sildenafil [8] Extensive hepatic metabolism (CYP3A4 major;
CYP2C9 minor); active metabolite (which is
50% ==as active as sildenafil) also undergoes
hepatic metabolism
No dose adjustment for mild to
moderate impairment is required.
Severe impairment has not been
studied
Hypotension; worsening of side effects
(epistaxis, headache, dyspepsia, flushing,
insomnia, erythema, dyspnea and/or rhinitis)
Hold or reduce dose if patient presents with
acute liver injury and hypotension.
Tadalafil [11] Hepatic metabolism via CYP3A to inactive
metabolites (which undergo methylation and
glucuronidation)
Child–Pugh class A or B: reduce
starting dose to 20 mg once per day
Hypotension; worsening of side effects
(headache)
Hold or reduce dose if patient presents with
acute liver injury and hypotension




Hepatic metabolism via CYP3A, CYP2C19, and
UGTs 1A9S, 2B7S an 1A3S; substrate OATP1B1
and OATP1B3; substrate but not an inhibitor of
P-glycoprotein
Not recommended in patients with
moderate or severe hepatic
impairment
Peripheral edema/fluid overload, nasal
congestion, sinusitis and/or flushing
Package labeling recommendation: discontinue if
aminotransferase elevations >5× ULN or if elevations
are accompanied by bilirubin >2× ULN, or by signs
or symptoms of liver dysfunction and other causes
are excluded
Bosentan [13] Eliminated by biliary excretion following
metabolism in the liver; three metabolites (one
active); induces CYP2C9, CYP34 and possibly
CYP2C19. Thought to induce its own
metabolism
Child–Pugh class A: no dosage
adjustment required
Peripheral edema/fluid overload, anemia,
respiratory tract infections
Package labeling: ALT/AST >5× and <8× ULN, stop
treatment and monitor ALT/AST levels at least every
2 weeks. Once the ALT/AST levels return to
pretreatment values, consider reintroduction of
the treatment
Child–Pugh class B or C: avoid use ALT/AST >8× ULN: discontinue treatment indefinitely
Macitentan
[13]
Metabolized primarily by oxidative
depropylation of the sulfamide to form the
pharmacologically active metabolite. This
reaction is dependent on CYP3A4 (major) and
CYP2C19 (minor)
No adjustment necessary Anemia, nasopharyngitis, pharyngitis,
bronchitis, headache, influenza, and urinary
tract infection
Package labeling: if clinically relevant aminotransferase
elevations occur, or if elevations are accompanied by
an increase in bilirubin >2× ULN, or by clinical
symptoms of hepatotoxicity, discontinue macitentan.
Consider reinitiation when hepatic enzyme levels
normalize in patients who have not experienced
clinical symptoms of hepatotoxicity
Soluble guanylate cyclase stimulator
Riociguat [19] Metabolized by CYP1A1, CYP3A, CYP2C8 and
CYP2J2. Formation of the major active
metabolite, M1, is catalyzed by CYP1A1; M1 is
further metabolized to the inactive N-
glucuronide.
Child–Pugh class A or B: no dosage
adjustment required. Child–Pugh class
B or C: no data available
Hypotension, bleeding or other side effects
(headache, dizziness, dyspepsia/gastritis,
nausea, diarrhea, hypotension, vomiting,
anemia, gastroesophageal reflux, and
constipation)
Hold or reduce dose if patient presents with




Rapid metabolism via hydrolysis at neutral pH
in blood (major), also subject to enzymatic
degradation (minor); two minimally active
metabolites (one from hydrolysis, one from
enzymatic degradation)
No adjustment necessary; if initiating
therapy, consider starting at the low
end of the dosing range and titrating
slowly
Possible hypotension or side effects
(headache, jaw pain, flushing)
Probably safe for use in patients with liver dysfunction;
consider dosage reduction if patient is hypotensive and
is experiencing increased side effects (flushing, headache,













Table 5 Monitoring and dosage of pulmonary arterial hypertension pharmacotherapy in hepatic impairment (Continued)
Treprostinil
[41]
Hepatic metabolism via CYP2C8 (major) and via
oxidation and glucuronidation (minor)
Mild to moderate hepatic insufficiency:
initial dose should be decreased to
0.625 ng/kg/minute ideal body weight;
cautious dosage increase
Hypotension or side effects (headache, jaw
pain, flushing)
Exposure is increased in patients with hepatic
insufficiency; if patient presents with acute liver injury
and signs of increased drug exposure (hypotension,
headache, flushing, jaw pain, and so forth), cautiously
and gradually decrease dosage until symptoms
subside. Do not abruptly discontinue therapy.
One reasonable approach is to decrease the treprostinil
dose by 10% every 3 hours until symptoms improve





Nonhepatic elimination No dosage adjustments
recommended/required




Hepatic metabolism via CYP2C8 (major) and via
oxidation and glucuronidation (minor)
Mild–moderate hepatic impairment:
up-titrate slowly when initiating. Severe
hepatic insufficiency: no studies
performed
Hypotension or worsening of side effects
(headache, jaw pain, flushing)
Exposure is increased in patients with hepatic
insufficiency; if patient presents with acute liver injury
and signs of increased drug exposure (hypotension,
headache, flushing, jaw pain, and so forth), increase
dosing interval and/or decrease inhalations per
treatment until symptoms subside
Iloprost,
inhaled [20]
Hepatic metabolism via β-oxidation (major)
and cytochrome P450 (minor); major metabol-
ite is inactive
Child–Pugh class B or C: consider
increasing the dosing interval (for
example, 3 to 4 hours between doses
depending on the patient’s response at
the end of the dose interval)
Hypotension/syncope, headache, flushing,
ALP/GGT increased, flu-like symptoms,
hemoptysis, muscle pain/cramping
Exposure is increased in patients with hepatic
insufficiency; if patient presents with acute liver injury
and signs of increased drug exposure (hypotension,
headache, jaw pain, and so forth), consider increasing
the dosing interval until symptoms subside
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transpeptidase; OATP, organic anion transporting polypeptide; UGT, uridine 5′-diphosphate
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http://ccforum.com/content/18/1/523multifactorial and potential etiologies include venous con-
gestion, hypotension (either from decreased cardiac output
or adverse medication effects) and the use of nephrotoxic
agents (for example, intravenous contrast, furosemide, and
so forth). Patients with PAH and acute renal failure may be
at risk for clinical deterioration from fluid overload and re-
sultant right heart strain. The provider must balance the
patient’s pulmonary status with the hemodynamic side
effects of PAH pharmacotherapy. Data regarding use of
phosphodiesterase type 5 inhibitors, endothelin-receptor
antagonists, intravenous prostacyclin therapy, soluble
guanylate cyclase stimulator and inhaled vasodilator ther-
apy in renal insufficiency and failure are summarized
in Table 4.
Acute hepatic impairment/failure
Liver injury is common among critically ill patients. At
ICU admission, liver function tests are found to be ab-
normal in as many as 61% of patients [43]. Cholestasis
(as determined by a bilirubin level >2 mg/dl) occurs in
20% of ICU patients during their ICU admission [44].
Additionally, hepatocellular injury in the ICU occurs fre-
quently, with hypoxic liver injury identified in up to 10%
of patients admitted to a medical ICU [45]. Other causes
of hepatocellular injury in critically ill patients include
congestive hepatopathy, septic shock and drug-induced
liver damage [46]. Patients with PAH are prone to devel-
oping congestive hepatopathy due to the likelihood of
right ventricular failure in this population. Furthermore,
medications such as bosentan have been implicated in
drug-induced hepatic injury, including cases of severe
hepatotoxicity [13,47]. The clinical impact of liver injury
on patients with PAH can be significant, as most medi-
cations used to treat PAH undergo hepatic metabolism.
Liver injury can impair drug metabolism and result in
drug toxicity. Furthermore, medications such as bosen-
tan have been implicated in drug-induced hepatic injury,
including cases of severe hepatotoxicity [13,47]. Table 5
describes the hepatic metabolism of phosphodiesterase
type 5 inhibitors, endothelin-receptor antagonists, sol-
uble guanylate cyclase stimulator, intravenous prostacyc-
lin therapy and inhaled vasodilator therapy, and provides
recommendations for the clinician regarding dosage ad-
justment and monitoring parameters.
Conclusions
The care of patients with PAH during critical illness is
complex due to their underlying disease and the nature of
pulmonary vasodilator therapy. This complexity is most
apparent in patients on prostacyclin therapy. As patients
with PAH live longer, the chance of admission for critical
illness will increase. During critical illness, managing PAH
medications can be very difficult, and consequences of
mistakes can be severe. After years of managing patientswith PAH through their critical illness, we have learned
some practices that are important to avoid and some prac-
tices that have generally helped us to navigate through dif-
ficult situations. There is little evidence to support our
recommendations on this topic – this article is therefore
not meant to be a practice guideline, because there is not
sufficient evidence to support our practice. We would en-
courage further discussion, and standardization of care is
encouraged for PAH patients on pulmonary vasodilators
during emergencies.
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